Institutional members access full text with Ovid®

Share this article on:

Diabetes Mellitus in Long-Term Survivors of Pediatric Hematopoietic Cell Transplantation

Hoffmeister, Paul A. MPH*; Storer, Barry E. PhD*; Sanders, Jean E. MD*†

Journal of Pediatric Hematology/Oncology: February 2004 - Volume 26 - Issue 2 - p 81-90
Oncology: Original Articles

To identify risk factors associated with the development of diabetes mellitus and to describe the prevalence of diabetes in pediatric hematopoietic cell transplant (HCT) survivors. The follow-up records of 748 patients who survived for at least 2 years after pediatric HCT were retrospectively reviewed for diagnosis of diabetes. Risk factors for type 2 diabetes were analyzed using multivariate statistics. Among 748 patients with a median of 11 years of follow-up, 38 developed diabetes after HCT. Four patients (three leukemia and one neuroblastoma) developed type 1 diabetes 8 to 14 years after HCT, at between 10 and 19 years of age. Thirty-four patients (32 leukemia and 2 aplastic anemia) developed type 2 diabetes 1 to 24 years after HCT, at between 11 and 41 years of age. Of the 34 patients with type 2 diabetes, 23 were non-Hispanic white, 3 had experienced asparaginase toxicity (hyperglycemia and/or pancreatitis), and 26 had a family history of diabetes. Risk factors associated with type 2 diabetes were diagnosis of acute or chronic leukemia, race/ethnicity other than non-Hispanic white, family history of diabetes, and asparaginase toxicity. The prevalence of type 1 diabetes among all surviving patients was 0.52%, or three times higher than the general U.S. population. The prevalence of type 2 diabetes was 9% among leukemia survivors and 2% among aplastic anemia survivors, both higher than expected. Pediatric HCT survivors are more likely to develop diabetes than the general population.

From the *Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington and the †Department of Pediatrics, University of Washington Medical School, Seattle, Washington.

Received for publication May 7, 2003; accepted August 14, 2003.

Supported in part by National Institutes of Health grant No. CA–18029 and the Jose Carreras International Leukemia Foundation.

Reprints: Jean E. Sanders, MD, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N. (D5-280), PO Box 19024, Seattle, WA 98109 (e-mail: jsanders@fhcrc.org).

© 2004 Lippincott Williams & Wilkins, Inc.